LXT-101

BACKGROUND The thermo-sensitive in situ gels based on copolymers are attractive as an injectable drug delivery carriers for… Expand

LXT-101, a cationic peptide is a novel antagonist of gonadotropin-releasing hormone (GnRH) for prostate cancer treatment. However… Expand

Objectives  Multivesicular liposomes (MVLs) are often used as an appropriate carrier for delivering peptides due to high drug… Expand

The introduction of luteinizing hormone-releasing hormone (LHRH) analogs and their antagonists is revolutionizing the treatment… Expand

Using a simple method to determine the interaction between peptide and lipid bilayer and then deciding how to modify formulation… Expand

This paper developed a sensitive and specific liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/MS) method… Expand

A sustained release poly(DL-lactide-co-glycolide) (PLGA) microsphere delivery system to treat prostate cancer for a luteinizing… Expand

LXT-101 is a newly developed GnRH (gonadotropin-releasing hormone) analogue. In this study, the in vivo pharmacological profile… Expand

AIM The biological characterization of LXT-101 was investigated in vivo using intact male rats and nude mice bearing xenografts… Expand

AIM: To investigate the pharmacological effect of LXT-101 on serum testosterone level in intact male rats. METHODS: Ratswere… Expand